SARcode Bioscience

Shire to acquire SARcode Bioscience, expand presence in ophthalmology

Monday, March 25, 2013

Global specialty biopharmaceutical company Shire has agreed to acquire SARcode Bioscience, a Brisbane, Calif.-based privately held biopharmaceutical company. The acquisition continues to build Shire’s presence in the ophthalmology therapeutic category and brings a new phase III compound—Lifitegrast—currently under development for the signs and symptoms of dry eye disease, into Shire’s portfolio.

[Read More]